Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.

Liu JH, Bian YM, Xie Y, Lu DP.

Mol Med Rep. 2015 Jul;12(1):1059-65. doi: 10.3892/mmr.2015.3526. Epub 2015 Mar 20.

2.

Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation.

Yang H, Qiu Q, Gao B, Kong S, Lin Z, Fang D.

J Exp Med. 2014 Nov 17;211(12):2467-79. doi: 10.1084/jem.20140283. Epub 2014 Nov 3.

3.

Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Pisapia L, Pozzo GD, Barba P, Citro A, Harris PE, Maffei A.

Results Immunol. 2012 Sep 27;2:174-83. doi: 10.1016/j.rinim.2012.09.001. eCollection 2012.

4.

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP.

Immunology. 2013 Oct;140(2):259-72. doi: 10.1111/imm.12136.

5.

ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells.

Yoon HS, Scharer CD, Majumder P, Davis CW, Butler R, Zinzow-Kramer W, Skountzou I, Koutsonanos DG, Ahmed R, Boss JM.

J Immunol. 2012 Sep 1;189(5):2393-403. doi: 10.4049/jimmunol.1103371. Epub 2012 Jul 30.

6.

Expression regulation of major histocompatibility complex class I and class II encoding genes.

van den Elsen PJ.

Front Immunol. 2011 Oct 4;2:48. doi: 10.3389/fimmu.2011.00048. eCollection 2011.

7.

Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.

Smith MA, Wright G, Wu J, Tailor P, Ozato K, Chen X, Wei S, Piskurich JF, Ting JP, Wright KL.

J Biol Chem. 2011 Mar 11;286(10):7893-904. doi: 10.1074/jbc.M110.165431. Epub 2011 Jan 7.

8.

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.

Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G, Mollejo M, García JF, Menarguez J, Montalbán C, Ruiz-Marcellan MC, Conde E, Piris MA.

Haematologica. 2010 Aug;95(8):1342-9. doi: 10.3324/haematol.2009.016113. Epub 2010 Apr 23.

9.

Functions of RANKL/RANK/OPG in bone modeling and remodeling.

Boyce BF, Xing L.

Arch Biochem Biophys. 2008 May 15;473(2):139-46. doi: 10.1016/j.abb.2008.03.018. Epub 2008 Mar 25. Review.

10.

MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, Bolick SC, Wright KL, Piskurich JF.

Mol Immunol. 2007 Apr;44(11):2923-32. Epub 2007 Feb 14.

11.

IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.

Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R.

J Clin Invest. 2007 Jan;117(1):122-32. Epub 2006 Dec 14.

Supplemental Content

Support Center